RT Journal Article
SR Electronic
T1 Current management of Barrett esophagus and esophageal adenocarcinoma
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 724
OP 732
DO 10.3949/ccjm.86a.18106
VO 86
IS 11
A1 Tavankit Singh
A1 Vedha Sanghi
A1 Prashanthi N. Thota
YR 2019
UL http://www.ccjm.org/content/86/11/724.abstract
AB Barrett esophagus is found in 5% to 15% of patients with gastroesophageal reflux disease and is a precursor of esophageal adenocarcinoma, yet the condition often goes undiagnosed. Patients with reflux disease who are male, over age 50, or white, and who smoke or have central obesity or a family history of Barrett esophagus or esophageal adenocarcinoma, should undergo initial screening endoscopy and, if no dysplasia is noted, surveillance endoscopy every 3 to 5 years. Dysplasia is treated with endoscopic eradication by ablation, resection, or both. Chemoprotective agents are being studied to prevent progression to dysplasia in Barrett esophagus. The authors discuss current recommendations for screening and management.